Personalized approach to drug therapy for multimorbid patients with left ventricular non-compaction cardiomyopathy
https://doi.org/10.25557/2073-7998.2020.05.25-27
Abstract
A left ventricular non-compaction cardiomyopathy (LVNC) is characterized by the development of a number of complications, which in combination with concomitant diseases usually leads to polypharmacy. Pharmacogenetic testing (PGT), aimed at identifying variants of genes associated with the metabolism of drugs, allows to choose the most effective and safe drug therapy in each case. The study includes 16 patients with LVNC, its complications and other diseases. All patients were assessed for 60 single nucleotide polymorphisms (SNPs) using real-time polymerase chain reaction in a QuantStudio 12KFlexReal-TimePCRSystem thermocycler (ThermoFisher Scientific, USA). According to the results of PGT 62.5% of the patients with LVNC and genotypes associated with a change in the metabolism of drugs were revealed. 12.5% of the patients had a history of taking drugs that required dose adjustment or replacement with another drug, taking into account the results of PGT.
About the Authors
A. V. Blokhina
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
A. I. Ershova
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
A. N. Meshkov
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
A. V. Kiseleva
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
R. P. Myasnikov
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
O. V. Kulikova
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
E. V. Zyatenkova
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
O. P. Skirko
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
M. V. Klimushina
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
E. A. Sotnikova
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
O. V. Kurilova
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
M. S. Pokrovskaya
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
O. M. Drapkina
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Review
For citations:
Blokhina A.V., Ershova A.I., Meshkov A.N., Kiseleva A.V., Myasnikov R.P., Kulikova O.V., Zyatenkova E.V., Skirko O.P., Klimushina M.V., Sotnikova E.A., Kurilova O.V., Pokrovskaya M.S., Drapkina O.M. Personalized approach to drug therapy for multimorbid patients with left ventricular non-compaction cardiomyopathy. Medical Genetics. 2020;19(5):25-27. (In Russ.) https://doi.org/10.25557/2073-7998.2020.05.25-27
Views:
454
Email this article 